Historical & Comparative Data
Reconciliation of Free cash flow before restructuring as disclosed in Appendix 5 in the Q4 2018 Press Release and the Free cash flow (CMD - Capital Markets Day definition)
2018 sales with new GBU structure
As previously communicated, Sanofi changed the organizational structure of two of its Global Business Units (GBU) to provide greater focus on its operations. The company created a new Primary Care GBU that combines the product portfolios of Sanofi’s existing Diabetes and Cardiovascular (DCV) GBU with Established Products in mature markets, which was part of the General Medicines & Emerging Markets (GEM) GBU. The new Primary Care unit will focus exclusively on mature markets. In addition, Sanofi created a second new global business unit called China & Emerging Markets. The two new GBUs were launched at the beginning of 2019.
In order to ensure the comparability of Sanofi’s GBUs in 2019 versus 2018, please find below an Excel file with 2018 sales reflecting the new GBU structure.
New segmentation and new IFRS15 revenue standard
Sanofi provides 2017 quarterly and full-year sales and earnings based on the new segmentation. This will also reflect the new IFRS15 revenue standard which becomes effective in 2018.
Change in Reporting of the Animal Health Business
Sales and Business net income statements for each quarter of 2015 and the first three quarters of 2016 with Animal Health Business reported on a separate line “Business net income of Animal Health Business”:
Sales Of Global Business Units
From Q1 2016, Sanofi will report sales of Global Business Units (GBU) - Diabetes & Cardiovascular, General Medicines & Emerging Markets, Sanofi Genzyme (Specialty Care), Sanofi Pasteur (Vaccines) and Merial (Animal Health) - and use a new geographic split.
Below are historical sales of GBUs by geographic region and product.
Change in Presentation of Vaxserve
VaxServe sales of non-Sanofi products are reported on the line Other revenues in the income statement from January 1, 2016. Accordingly, prior period comparative net sales have been reclassified to the line Other revenues.
In order to ensure the comparability of Sanofi’s Global Franchises, Aggregate Company Sales and Aggregate Other Revenues, please find below: